

Substitute for form 1449/PTO THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/531,049 (Nat'l Phase of Appl. No. PCT/CN2002/000728)
				Filing Date	§ 371 Date: January 17, 2006
				First Named Inventor	LIANG, Jingyu
				Art Unit	1615
				Examiner Name	KEYS, Rosalynd Ann
Sheet	1	of	1	Attorney Docket Number	2108.0060000/MAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL14	Dow Water Solutions, affiliate of The Dow Chemical Company, "Additional DOWEX Ion Exchange Resins," available online at http://www.dow.com/liquidseps/prod/supp_ix.htm , 3 pages, The Dow Chemical Company (accessed on December 19, 2006)	
	NPL15	Campbell, W.W., <i>et al.</i> , "Effects of oral pinitol supplementation on oral and intravenous glucose tolerance in older people," <i>FASEB J. Abstr.</i> 16:A24, Abstract No. 51.7, The Federation of American Societies for Experimental Biology (March 2002)	
	NPL16	Campbell, W.W., <i>et al.</i> , "Pinitol Supplementation Does Not Affect Insulin-Mediated Glucose Metabolism and Muscle Insulin Receptor Content and Phosphorylation in Older Humans," <i>J. Nutr.</i> 134:2998-3003, American Society of Nutritional Sciences (November 2004)	
	NPL17	Davis, A., <i>et al.</i> , "Effect of Pinitol Treatment on Insulin Action in Subjects With Insulin Resistance," <i>Diabetes Care</i> 23:1000-1005, American Diabetes Association (2000)	
	NPL18	"Entry Name: Chiro-Inositol," <i>Combined Chemical Dictionary on CD-Rom</i> , Version 8.1, 1 page, Chapman & Hall (2004)	
	NPL19	Kim, J.-I., <i>et al.</i> , "Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study," <i>Eur. J. Clin. Nutr.</i> 59:456-458, Nature Publishing Group (March 2005)	
	NPL20	O'Neil, M.J., <i>et al.</i> , eds., "Inositol," <i>The Merck Index</i> , 13 th Ed., Merck & Co., Inc., Whitehouse Station, NJ, 1 page (October 2001)	
	NPL21	Plourde, R., <i>et al.</i> , "Synthesis and Characterization of an Insulin-Mimetic Disaccharide," <i>J. Org. Chem.</i> 57:2606-2610, American Chemical Society (1992)	

927323v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.